Related Experiment Videos
In vivo antitumor activity of ilmofosine
D B Herrmann1, W Pahlke, H G Opitz
1Boehringer Mannheim GmbH, Department of Immunopharmacology, F.R.G.
Cancer Treatment Reviews
|September 1, 1990
Summary
Ilmofosine, a novel thioether phospholipid, demonstrates significant in vivo antitumour and antimetastatic activity against fibrosarcoma and lung carcinoma. Its cytotoxic effects are enhanced when combined with other chemotherapy agents.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative.
- Investigating novel therapeutic agents for cancer treatment is crucial.
Purpose of the Study:
- To evaluate the in vivo antitumour activity of Ilmofosine.
- To assess the antineoplastic and antimetastatic properties of Ilmofosine.
- To examine the synergistic effects of Ilmofosine in combination with other chemotherapeutics.
Main Methods:
- In vivo studies using methylcholanthrene (MethA)-induced fibrosarcoma and 3Lewis-lung carcinoma models.
- Oral administration of Ilmofosine at doses ranging from 0.625 to 40 mg/kg/day.
- Combination therapy with Ilmofosine (p.o.) and cyclophosphamide (p.o.) or cis-diamminedichloroplatinum (cis-DDP) (i.v.).
Main Results:
- Ilmofosine exhibited significant antineoplastic and antimetastatic effects in both tested tumour systems.
- Synergistic antitumour effects were observed when Ilmofosine was combined with cyclophosphamide or cis-DDP.
- The primary mechanism of action for Ilmofosine appears to be direct cytostatic/cytotoxic effects.
Conclusions:
- Ilmofosine possesses in vivo antitumour activity in relevant cancer models.
- Combination therapy with Ilmofosine and other cytotoxic agents can enhance therapeutic outcomes.
- Ilmofosine represents a promising candidate for further investigation in cancer therapy.